MAJOR MOVES! FDA Approves Gilead’s Bixlenvo, Expanding Once-Daily HIV Treatment Options

For people living with HIV, treatment has transformed dramatically over the past several decades. Now, another option is entering the conversation, particularly for adults who have maintained viral suppression but have been managing their HIV through more complicated treatment regimens.

The U.S. Food and Drug Administration approved Gilead Sciences’ Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg) on August 27, giving eligible adults with virologically suppressed HIV-1 a new once-daily single-tablet treatment option. Gilead says Bixlenvo is now the smallest single-tablet regimen available for HIV treatment in the United States.

The approval is particularly notable for people who have been unable to simplify their treatment using currently available single-tablet regimens because of factors that can include previous antiretroviral resistance or tolerability challenges.

Why the New Approval Matters

HIV treatment has come a long way from the complex medication schedules that many longtime survivors once faced. Today, many people living with HIV are able to manage the virus with one pill each day.

But that experience is not universal.

Some people whose HIV is already virologically suppressed still rely on combinations of multiple medications. In Gilead’s ARTISTRY-1 clinical trial, participants entered the study taking between two and 11 pills daily, and about 40% were taking antiretroviral medications more than once per day. The median participant had also been receiving HIV treatment for 28 years.

Bixlenvo provides a potential way to consolidate treatment for eligible patients into one daily tablet after a two-day initiation regimen that also includes Sunlenca (lenacapavir).

For a community that is living longer with HIV, simplifying treatment can take on additional importance as people manage other medications and health considerations that may come with aging.

A Treatment Option Designed With Longtime Patients in Mind

One of the notable aspects of Bixlenvo’s development was the population included in the ARTISTRY-1 trial.

According to Gilead, ARTISTRY-1 enrolled the oldest population to date in a registrational Phase 3 HIV treatment trial, with participants having a median age of 60. Many had extensive treatment histories and previous antiretroviral resistance.

That matters because the story of HIV in America increasingly includes people who have been living with and treating the virus for decades.

Bixlenvo is approved as a complete regimen to replace an existing antiretroviral regimen in adults with HIV-1 who are virologically suppressed, defined as having HIV-1 RNA below 50 copies per mL, on a stable regimen and who have no known or suspected resistance to the individual components of Bixlenvo.

It is not a cure for HIV or AIDS.

How Bixlenvo Works

Bixlenvo combines two medicines, bictegravir and lenacapavir, that target different stages of the HIV life cycle.

Bictegravir is an integrase strand transfer inhibitor, while lenacapavir is a first-in-class capsid inhibitor. Bringing the two together gives eligible patients a single daily oral treatment designed to maintain viral suppression.

The FDA’s decision was supported by the Phase 3 ARTISTRY-1 and ARTISTRY-2 clinical trials. Both evaluated Bixlenvo among adults whose HIV was already virologically suppressed, including people switching from complex multi-tablet regimens and people switching from Biktarvy.

At 48 weeks, the trials found Bixlenvo maintained virologic suppression at comparable levels and was generally well tolerated. In ARTISTRY-1, 0.8% of participants who switched to bictegravir/lenacapavir had HIV-1 RNA of at least 50 copies/mL compared with 1.1% of those who remained on their complex antiretroviral regimens. No participant developed emergent resistance during that period.

More Choices in the Future of HIV Care

The approval also represents another step in Gilead’s larger strategy surrounding lenacapavir.

The company is developing multiple approaches intended to give people greater flexibility in how HIV is treated, including daily medication, potential weekly oral options and longer-acting approaches.

That flexibility matters because HIV care is not one-size-fits-all. A regimen that works well for one person may not be appropriate for another based on resistance history, other medications, tolerability and individual health needs.

Bixlenvo also has important safety considerations. Gilead reports that the most common adverse reactions in clinical trials were headache, nausea and diarrhea. The medication has contraindications and potential drug interactions, meaning treatment decisions should be made with an HIV healthcare provider who can review an individual’s complete medical and medication history.

Nearly 30 years after combination antiretroviral therapy began dramatically changing what it meant to live with HIV, advances in treatment continue to focus not only on keeping the virus suppressed, but also on making long-term care more manageable.

For eligible adults who have spent years navigating complex treatment regimens, Bixlenvo represents another option and another sign of how far HIV medicine continues to evolve.

SNUBB3D’s Perspective

At SNUBB3D Magazine, we are excited to see continued advancements in HIV treatment and care. Our communities matter, and so does access to information, healthcare and treatment options that can improve quality of life. HIV has deeply impacted communities of color and LGBTQ+ communities for generations, making progress in treatment especially meaningful to many of the people we serve and celebrate through our platform. We believe stories like this deserve visibility because HIV awareness is about more than statistics. It is about people, families, longevity and ensuring that those living with HIV know they deserve to live full, healthy and empowered lives.